Tetracyclines inhibit rat osteoclast formation and activity in vitro and affect bone turnover in young rats in vivo
- PMID: 20033141
- DOI: 10.1007/s00223-009-9328-5
Tetracyclines inhibit rat osteoclast formation and activity in vitro and affect bone turnover in young rats in vivo
Abstract
An experiment was designed to investigate whether systemic administration of tetracyclines (TCs) as bone fluorochrome labels could interfere with bone modeling in vivo and inhibit osteoclast formation and activity in vitro. Cell cultures of rat bone marrow macrophages revealed that TC and oxytetracycline inhibited osteoclastogenesis and bone resorption and stimulated apoptosis. Forty rats in five groups were treated with saline, calcein green, alizarin red S, TC, or oxytetracycline. Their tibias were used for histomorphometric analysis, including bone static, dynamic, and resorption parameters in the tibial proximal metaphysis. No significant differences in bone volume per tissue volume, trabecular number, trabecular thickness, trabecular separation, bone formation rate per bone surface, mineralizing surface, or mineral apposition rate were observed. TC or oxytetracycline decreased eroded surface, number of osteoclasts per bone perimeter, and osteoclast surface per bone surface by about 50%. The results demonstrated that TC and oxytetracycline inhibit rat osteoclast formation and activity in vitro, and histomorphometric parameters involved in bone turnover may be affected by the use of oxytetracycline and TC as fluorescent bone labels in vivo.
Similar articles
-
Climbing exercise increases bone mass and trabecular bone turnover through transient regulation of marrow osteogenic and osteoclastogenic potentials in mice.J Bone Miner Res. 2003 Nov;18(11):2002-9. doi: 10.1359/jbmr.2003.18.11.2002. J Bone Miner Res. 2003. PMID: 14606513
-
Effects of tetracyclines on bones: an ambiguous question needs to be clarified.Pharmazie. 2012 May;67(5):457-9. Pharmazie. 2012. PMID: 22764582 Review.
-
Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats.J Bone Miner Res. 2007 Jun;22(6):849-59. doi: 10.1359/jbmr.070302. J Bone Miner Res. 2007. PMID: 17352644
-
Minocycline impairment of both osteoid tissue removal and osteoclastic resorption in a synchronized model of remodeling in the rat.J Cell Physiol. 1996 May;167(2):359-68. doi: 10.1002/(SICI)1097-4652(199605)167:2<359::AID-JCP22>3.0.CO;2-1. J Cell Physiol. 1996. PMID: 8613479
-
Reduced bone formation and increased bone resorption: rational targets for the treatment of osteoporosis.Osteoporos Int. 2003;14 Suppl 3:S2-8. doi: 10.1007/s00198-002-1340-9. Epub 2003 Mar 19. Osteoporos Int. 2003. PMID: 12730770 Review.
Cited by
-
Validation of urinary calcium isotope excretion from bone for screening anabolic therapies for osteoporosis.Osteoporos Int. 2014 Oct;25(10):2471-5. doi: 10.1007/s00198-014-2790-6. Epub 2014 Jun 27. Osteoporos Int. 2014. PMID: 24969137
-
Doxycycline reduces osteopenia in female rats.Sci Rep. 2019 Oct 25;9(1):15316. doi: 10.1038/s41598-019-51702-y. Sci Rep. 2019. PMID: 31653893 Free PMC article.
-
Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo.Exp Cell Res. 2011 Jun 10;317(10):1454-64. doi: 10.1016/j.yexcr.2011.03.014. Epub 2011 Mar 21. Exp Cell Res. 2011. PMID: 21420951 Free PMC article.
-
Tetracyclines and bone: Unclear actions with potentially lasting effects.Bone. 2022 Jun;159:116377. doi: 10.1016/j.bone.2022.116377. Epub 2022 Mar 3. Bone. 2022. PMID: 35248788 Free PMC article. Review.
-
Clinically relevant doses of tiludronate do not affect bone remodelling in pasture-exercised horses.Equine Vet J. 2025 Mar;57(2):513-521. doi: 10.1111/evj.14119. Epub 2024 Jun 25. Equine Vet J. 2025. PMID: 38924597 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources